Another Pharma Begins Late-Stage COVID Vax Trial

Reuters reports:

Novavax has begun a large late-stage study of its experimental Covid-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in scaling up the manufacturing process.

It will enroll up to 30,000 volunteers across about 115 sites in the United States and Mexico, with two-thirds of them receiving the shot 21 days apart and the rest getting placebo, the company said.

Novavax lags behind other drugmakers in the global race for COVID-19 vaccine, with shots from Pfizer and Moderna authorized for emergency use in the United States.

Novavax starts late-stage trial of COVID-19 vaccine in United States https://t.co/A0ggFKFaCH pic.twitter.com/vm335uvj78

— Reuters (@Reuters) December 28, 2020